This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Chemo-Sero-Therapeutic Research Institute, Nof Corporation. Active years: 1998-2000.
Location History:
- Kumamoto-ken, JP (1998)
- Kumamoto, JP (2000)
Company Filing History:
2 out of 151 
1 out of 344 
Years Active: 1998-2000
Title: Kozo Takase: Innovator in Infectious Disease Research
Introduction
Kozo Takase is a prominent inventor based in Japan, recognized for his contributions to the field of infectious disease research. His work focuses on developing novel vaccines to combat specific viral strains that are not effectively addressed by conventional methods.
Latest Patents
Takase's notable patent is titled "Novel Infectious Bursal Disease Virus And Vaccine Containing Said Virus." This patent describes the isolation of a novel infectious bursal disease (IBD) virus that is not protectable by existing IBD vaccines. The patent outlines the development of a vaccine that is effective against this newly identified virus. The TY2 strain of the IBD virus was isolated, and its passage strains were obtained. This strain exhibits a distinct genetic type, particularly in a hypervariable region of the VP2 protein, which is crucial for host protection. The TY2 strain allows for the production of an excellent vaccine against IBD.
Career Highlights
Kozo Takase is affiliated with the Chemo-Sero-Therapeutic Research Institute, where he conducts his research and development activities. His work has significantly advanced the understanding of IBD and the creation of effective vaccines.
Collaborations
Throughout his career, Takase has collaborated with notable colleagues, including Kenichi Yamazaki and Hideyuki Ohta. These collaborations have contributed to the advancement of research in infectious diseases and vaccine development.
Conclusion
Kozo Takase's innovative work in the field of infectious disease research highlights the importance of developing effective vaccines against novel viral strains. His contributions continue to impact the scientific community and public health positively.